Latest Breaking News On - Entasis therapeutics inc - Page 1 : comparemela.com

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on.

Hong kongNew zealandRepublic ofUnited statesHarald reinhartMatt ronsheimAcinetobacter baumanniiCenters for diseaseHead of global developmentZai lab limitedZai labSecurities exchangeInnoviva incDrug administrationZai lab forwardExchange commission

Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+

Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.

Harald reinhartEntasis therapeutics incChina national medical products administrationHead of global developmentZai labZai lab new drug applicationDrug administrationZai lab ltdMore such health newsWorld health organizationInnoviva specialty therapeuticsNational medical products administrationNew drug applicationGreater chinaGlobal developmentInfectious diseases

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesNew zealandUnited kingdomRepublic ofAcinetobacter baumanniiHarald reinhartMatt ronsheimDrug administrationZai lab limitedHealth organizationCenters for diseaseZai lab new drug applicationEntasis therapeutics incZai labHead of global development

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South africaComunidad autonoma de catalunaUnited kingdomSarah mcleodDavid pattiAlison luckeyDennis riedlGabrielle kornmanDavid altaracHealth emergency preparednessGlobal antibiotic research development partnershipInnoviva incFoundation in genevaUs centers for diseaseInnoviva specialty therapeutics incInfectious disease global congress

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to T

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care.Positive top-line study results are a significant milestone in the development of a first-in-class antibiotic against drug-resi.

South africaUnited kingdomUnited statesGrand duchy of luxembourgManica balasegaramDavid pattiPavel raifeldGlobal antibiotic research development partnershipLeo model foundationCorporate communicationsAfrican medical research councilUs national institute of allergyEntasis therapeutics incPublic health agency of canadaDrug administrationWorld health organization